Antibody

7개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved7 programs
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
AntibodyLimited DatastaleAntengene Therapeutics LimitedPhase 1

nivolumab (Opdivo, ATG-017+Nivolumab)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Discontinued
AntibodyLimited DatastaleJanssenPhase 1

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex Faspro (Daratumumab and hyaluronidase-fihj))

Hematologic Malignancy; Bone Marrow Transplant Rejection · Hematologic Malignancy

#HematologicMalignancy#Antibody#Phase1#monoclonal-antibody#BoneMarrowTransplantRejection+1
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

nivolumab (Opdivo, TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Nivolumab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastalePfizerPhase 1

PF-07901800 (TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Rituximab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleChinese PLA General HospitalPhase 2

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase2#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Active